How big is the aquaculture vaccines industry?

The global aquaculture vaccines market size is expected to increase USD 1,063.64 million by 2033 from USD 470 million in 2023. Read More

What will be the CAGR of global aquaculture vaccines industry?

The global aquaculture vaccines market will register a growth rate of 8.51% between 2024 and 2033. Read More

Who are the prominent players operating in the aquaculture vaccines market?

The major players operating in the aquaculture vaccines market are Zoetis Inc., Phibro Animal Health Corporation, Elanco, Merck & Co., Inc., KBNP, CAVAC, Kyoto Biken Laboratories, Inc., Nisseiken Co., Ltd., Vaxxinova International BV, HIPRA, Tecnovax, Virbac, Veterquimica S.A and Others. Read More

Which are the driving factors of the aquaculture vaccines market?

The driving factors of the aquaculture vaccines market are the rising aquaculture businesses in developing countries and replicative antigen delivery system. Read More

Which region will lead the global aquaculture vaccines market?

Europe region will lead the global aquaculture vaccines market during the forecast period 2024 to 2033. Read More

Aquaculture Vaccines Market Size, Share, and Trends 2024 to 2033

Aquaculture Vaccines Market (By Type of Vaccines: Inactivated Vaccines, Live Vaccines, Others; By Route of Administration: Immersion Vaccines, Injection Vaccines, Oral Vaccines; By Application: Bacterial Infection, Viral Infection, Others; By Species: Salmon, Trout, Tilapia Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Last Updated : June 2024
Report Code : 4423
Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Aquaculture Vaccines Market

5.1. COVID-19 Landscape: Aquaculture Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Aquaculture Vaccines Market, By Type of Vaccines

8.1. Aquaculture Vaccines Market Revenue and Volume Forecast, by Type of Vaccines, 2024-2033

8.1.1. Inactivated Vaccines

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Live Vaccines

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Aquaculture Vaccines Market, By Route of Administration

9.1. Aquaculture Vaccines Market Revenue and Volume Forecast, by Route of Administration, 2024-2033

9.1.1. Immersion Vaccines

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Injection Vaccines

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Oral Vaccines

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Aquaculture Vaccines Market, By Application

10.1. Aquaculture Vaccines Market Revenue and Volume Forecast, by Application, 2024-2033

10.1.1. Bacterial Infection

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Viral Infection

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Aquaculture Vaccines Market, By Species

11.1. Aquaculture Vaccines Market Revenue and Volume Forecast, by Species, 2024-2033

11.1.1. Salmon

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Trout

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Tilapia

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Aquaculture Vaccines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by Species (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Type of Vaccines (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by Species (2021-2033)

Chapter 13. Company Profiles

13.1. Zoetis Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Phibro Animal Health Corporation

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Elanco

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Merck & Co., Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. KBNP

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Abbott

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Nisseiken Co., Ltd.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Vaxxinova International BV

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. HIPRA

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

We use cookies to improve your experience

Aquaculture Vaccines Market Size to Hit USD 1,063.64 Mn By 2033

List of Contents